{
    "clinical_study": {
        "@rank": "109118", 
        "arm_group": [
            {
                "arm_group_label": "estradiol plus MPA", 
                "arm_group_type": "Active Comparator", 
                "description": "1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 4mg medroxyprogesterone acetate, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.\nestradiol valerate, 1mg*21/box medroxyprogesterone acetate, 2mg*100/bottle"
            }, 
            {
                "arm_group_label": "estradiol plus progesterone", 
                "arm_group_type": "Experimental", 
                "description": "1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 200mg progesterone capsule, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.\nestradiol valerate, 1mg*21/box progesterone capsule, 100mg*6/box"
            }, 
            {
                "arm_group_label": "Ximingting tablet", 
                "arm_group_type": "Experimental", 
                "description": "1 tablet of cimicifuga rhizoma extract, tid 100mg*15*2/box The anticipated duration is 2 years."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the benefit/risk of  hormone replacement treatment among early\n      menopausal women in China. This is a multi-centre, random, prospective study."
        }, 
        "brief_title": "Multi-centre Clinical Trial on Hormone Replacement Treatment in China", 
        "condition": [
            "Menopausal Syndrome", 
            "Cardiovascular Disease", 
            "Osteoporosis", 
            "Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Cardiovascular Diseases", 
                "Osteoporosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  going through amenorrhea above 6 months and within 5 years,\n\n          -  aged 40 to 60 years,\n\n          -  going though postmenopausal symptoms,\n\n          -  serum E2 concentration <30pg/ml,\n\n          -  serum FSH concentration >40IU/L.\n\n        Exclusion Criteria:\n\n          -  uterine fibroid diameter\u22655cm,\n\n          -  history of diabetes or hypertension,\n\n          -  history of thromboembolism, severe endometriosis, epilepsy, asthma,\n             hyperprolactinemia,\n\n          -  first degree relative had a history of breast cancer,\n\n          -  being in severe or unstable condition of somatic diseases,\n\n          -  receiving HRT in the past 3 month,\n\n          -  drug or alcohol abuse in the past 3 month,\n\n          -  endometrial thickness \u22650.5cm after withdrawal bleeding,\n\n          -  being allergic to the medicine,\n\n          -  participating in other clinical trials within 1 month ago."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "1200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698164", 
            "org_study_id": "2008BAI57B04"
        }, 
        "intervention": [
            {
                "arm_group_label": "estradiol plus MPA", 
                "description": "Participants are given estradiol and synthetic progestin.", 
                "intervention_name": "estradiol plus MPA", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ximingting tablet", 
                "description": "Participants are given phytoestrogen.", 
                "intervention_name": "Ximingting Tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "estradiol plus progesterone", 
                "description": "Participants are given estradiol and natural progesterone.", 
                "intervention_name": "estradiol plus progesterone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Hormones", 
                "Progesterone", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate", 
                "Medroxyprogesterone Acetate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "lipid profiles", 
            "coronary heart disease", 
            "menopausal syndrome", 
            "MMSE", 
            "MENQOL", 
            "HAD"
        ], 
        "lastchanged_date": "September 28, 2012", 
        "location": {
            "contact": {
                "email": "xuewei8955@sina.com", 
                "last_name": "Wei Xue, Bachelor Degree"
            }, 
            "facility": {
                "address": {
                    "city": "Peking", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100730"
                }, 
                "name": "PUMCH"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Multi-centre Clinical Trial on Hormone Replacement Treatment in China", 
        "other_outcome": [
            {
                "description": "ultrasonography", 
                "measure": "Change from Baseline in thickness of endometrium at 12 months and 24 months", 
                "safety_issue": "Yes", 
                "time_frame": "before the treatment, time point of taking the medicine for 1 year, time point of taking the medicien for 2 years"
            }, 
            {
                "description": "diary", 
                "measure": "uterine bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "every three months after taking the medicine until two years later"
            }, 
            {
                "description": "height, weight, heart rate, BP, gynecological examination", 
                "measure": "Change from Baseline in vital signs every three months", 
                "safety_issue": "Yes", 
                "time_frame": "before the recruitment, before handing out the mecidcine, every three months after taking the medicine till two years later"
            }, 
            {
                "description": "liver function, renal function", 
                "measure": "Change from Baseline in general health at 12 months and 24 months", 
                "safety_issue": "Yes", 
                "time_frame": "before the treatment, time point of taking the medicine for 1 year, time point of taking the medicien for 2 years"
            }
        ], 
        "overall_contact": {
            "email": "zhengtingping@gmail.com", 
            "last_name": "Tingping Zheng, Bachelor Degree"
        }, 
        "overall_official": {
            "affiliation": "Peking Union Medical College Hospital", 
            "last_name": "Aijun Sun, PH.D   M.D", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "lipid profiles, high-sensitivity C-reactive protein, Hemoglobin A1C, fasting glucose, fasting insulin, blood pressure, waistline, hipline, body composition, electrocardiogram, incidence of coronary heart disease", 
                "measure": "Change from Baseline in risk factors of cardiovascular disease at 12 months and 24 months", 
                "safety_issue": "Yes", 
                "time_frame": "before the treatment, time point of taking the medicine for 1 year, time point of taking the medicine for 2 years"
            }, 
            {
                "description": "Mammography, palpation of breast, incidence of breast cancer", 
                "measure": "Change from Baseline in risk factors of breast cancer at 12 months and 24 months", 
                "safety_issue": "Yes", 
                "time_frame": "before the treatment, time point of taking the medicine for 1 year, time point of taking the medicien for 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698164"
        }, 
        "secondary_outcome": [
            {
                "description": "DEXA bone mineral density", 
                "measure": "Change from Baseline in BMD at 12 months and 24 months", 
                "safety_issue": "No", 
                "time_frame": "before the treatment, time point of taking the medicine for 1 year, time point of taking the medicien for 2 years"
            }, 
            {
                "description": "mini-mental state examination, hospital anxiety and depression scale", 
                "measure": "Change from Baseline in risk factors of senile dementia every three months", 
                "safety_issue": "No", 
                "time_frame": "before the recruitment, before handing out the mecidcine, every three months after taking the medicine till two years later"
            }, 
            {
                "description": "Kupperman menopause index, RAND36 Menopause-Specific quality of life questionaire", 
                "measure": "Change from Baseline in the quality of life every three months", 
                "safety_issue": "No", 
                "time_frame": "before the recruitment, before handing out the mecidcine, every three months after taking the medicine till two years later"
            }
        ], 
        "source": "Peking Union Medical College Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking Union Medical College Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}